Curcumin attenuates amyloid-β-induced tau hyperphosphorylation in human neuroblastoma SH-SY5Y cells involving PTEN/Akt/GSK-3β signaling pathway

Journal of Receptors and Signal Transduction

Volumn 34, Issue 1, 2014, Pages 26-37

  Huang, Han Chang ^a   Tang, Di ^a   Xu, Ke ^b   Jiang, Zhao Feng ^a  

^a BEIJING UNION UNIVERSITY   (China)

^b CAPITAL NORMAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid ; Curcumin; GSK 3 ; PTEN; Tau hyperphosphorylation

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; CURCUMIN; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE 6; INSULIN RECEPTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN P55; PROTEIN P85; TAU PROTEIN;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL STRESS; CONTROLLED STUDY; DOWN REGULATION; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; OXIDATIVE STRESS; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

AMYLOID BETA-PEPTIDES; CURCUMIN; GLYCOGEN SYNTHASE KINASE 3; HUMANS; NEUROBLASTOMA; NEURONS; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84893118788     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2013.848891     Document Type: Article

References (41)

1. Huang HC, Jiang ZF. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J Alzheimers Dis 2009;16:15-27.
2. Huang HC, Jiang ZF. Amyloid-beta protein precursor family members: a review from homology to biological function. J Alzheimers Dis 2011;26:607-26.
3. Smith RP, Higuchi DA, Broze GJ, Jr. Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science 1990;248:1126-8.
4. Small DH, Clarris HL, Williamson TG, et al. Neurite-outgrowth regulating functions of the amyloid protein precursor of Alzheimer's disease. J Alzheimers Dis 1999;1:275-85.
5. Seabrook GR, Smith DW, Bowery BJ, et al. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology 1999; 38:349-59.
6. Gralle M, Ferreira ST. Structure and functions of the human amyloid precursor protein: the whole is more than the sum of its parts. Prog Neurobiol 2007;82:11-32.
7. Rama N, Goldschneider D, Corset V, et al. Amyloid precursor protein regulates netrin-1-mediated commissural axon outgrowth. J Biol Chem 2012;287:30014-23.
8. Garci'a-Sierra F, Jarero-Basulto JJ, Kristofikova K, et al. Ubiquitin is associated with early truncation of tau protein at aspartic acid421 during the maturation of neurofibrillary tangles in Alzheimer's disease. Brain Pathol 2012;22:240-50.
9. Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 1992;8(1):159-68.
10. Buee L, Bussiere T, Buee-Scherrer V, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000;33:95-130.
11. Shipton OA, Leitz JR, Dworzak J, et al. Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci 2011;31:1688-92.
12. Tai HC, Serrano-Pozo A, Hashimoto T, et al. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 2012;181:1426-35.
13. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-5.
14. Dong S, Duan Y, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener 2012;1:18.
15. Yanagisawa D, Taguchi H, Yamamoto A, et al. Curcuminoid binds to amyloid-beta1-42 oligomer and fibril. J Alzheimers Dis 2011;24: 33-42.
16. Mutsuga M, Chambers JK, Uchida K, et al. Binding of curcumin to senile plaques and cerebral amyloid angiopathy in the aged brain of various animals and to neurofibrillary tangles in Alzheimer's brain. J Vet Med Sci 2012;74:51-7.
17. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892-901.
18. Zhang C, Browne A, Child D, Tanzi RE. Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem 2010;285: 28472-80.
19. Liu H, Li Z, Qiu D, et al. The inhibitory effects of different curcuminoids on beta-amyloid protein, beta-amyloid precursor protein and beta-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells. Neurosci Lett 2010;485: 83-8.
20. Wang Y, Yin H, Wang L, et al. Curcumin as a potential treatment for Alzheimer's disease: a study of the effects of curcumin on hippocampal expression of glial fibrillary acidic protein. Am J Chin Med 2013;41:59-70.
21. Huang HC, Chang P, Dai XL, Jiang ZF. Protective effects of curcumin on amyloid-beta-induced neuronal oxidative damage. Neurochem Res 2012;37:1584-97.
22. Huang HC, Xu K, Jiang ZF. Curcumin-mediated neuroprotection against amyloid-beta-induced mitochondrial dysfunction involves the inhibition of GSK-3beta. J Alzheimers Dis 2012; 32:981-96.
23. Flugel D, Gorlach A, Kietzmann T. GSK-3beta regulates cell growth, migration, and angiogenesis via Fbw7 and USP28- dependent degradation of HIF-1alpha. Blood 2012;119: 1292-301.
24. Itoh S, Saito T, Hirata M, et al. GSK-3alpha and GSK-3beta proteins are involved in early stages of chondrocyte differentiation with functional redundancy through RelA protein phosphorylation. J Biol Chem 2012;287:29227-36.
25. Durairajan SS, Liu LF, Lu JH, et al. Berberine ameliorates betaamyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model. Neurobiol Aging 2012;33:2903-19.
26. Terwel D, Muyllaert D, Dewachter I, et al. Amyloid activates GSK- 3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol 2008;172:786-98.
27. Dominguez JM, Fuertes A, Orozco L, et al. Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem 2012;287:893-904.
28. Danysz W, Parsons CG. Alzheimer's disease, beta-amyloid, glutamate, NMDA receptors and memantine - searching for the connections. Br J Pharmacol 2012;167:324-52.
29. den Heijer T, Vermeer SE, van Dijk EJ, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003;46:1604-10.
30. Haan MN. Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol 2006;2: 159-66.
31. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2012;9:35-66.
32. Liu S, Liu Y, Hao WL, et al. TLR2 is a primary receptor for Alzheimer's amyloid b peptide to trigger neuroinflammatory activation. J. Immunol 2012;188:1098-107.
33. Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca(2) elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines. J Neurosci 2010;30:11938-50.
34. Alberdi E, Sanchez-Gomez MV, Cavaliere F, et al. Amyloid beta oligomers induce Ca2 dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 2010;47: 264-72.
35. Small DH, Gasperini R, Vincent AJ, et al. The role of Abetainduced calcium dysregulation in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 2009;16:225-33.
36. Mota SI, Ferreira IL, Pereira C, et al. Amyloid-beta peptide 1-42 causes microtubule deregulation through N-methyl-D-aspartate receptors in mature hippocampal cultures. Curr Alzheimer Res 2012;9:844-56.
37. Kervern M, Angeli A, Nicole O, et al. Selective impairment of some forms of synaptic plasticity by oligomeric amyloid-beta peptide in the mouse hippocampus: implication of extrasynaptic NMDA receptors. J Alzheimers Dis 2012;32(1):183-96.
38. Choi SH, Park KW, Na DL, et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. Curr Med Res Opin 2011;27: 1375-83.
39. Mohamed A, Posse de Chaves E. Abeta internalization by neurons and glia. Int J Alzheimers Dis 2011;2011:127984.
40. Gu XM, Huang HC, Jiang ZF. Mitochondrial dysfunction and cellular metabolic deficiency in Alzheimer's disease. Neurosci Bull 2012;28:631-40.
41. Yan SD, Fu J, Soto C, et al. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature 1997;389:689-95.